D0320: High Dose Interleukin-2 (IL-2) Therapy in "Lymphodepleted Primed" Patients With Metastatic Melanoma.

Trial Profile

D0320: High Dose Interleukin-2 (IL-2) Therapy in "Lymphodepleted Primed" Patients With Metastatic Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2013

At a glance

  • Drugs Aldesleukin (Primary) ; Cyclophosphamide; Fludarabine; Granulocyte colony-stimulating factors
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jun 2007 Status changed from recruiting to in progress.
    • 30 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top